TBX5 and adrenal cortex carcinoma: The pan-cancer validation outcomes indicated that TBX5-AS1 was linked to survival in four tumors, namely, adrenocortical carcinoma (ACC), LUAD, lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC).